Overall, antigens expressed by the DNA vaccines primarily include TAAs (12/20, 60%), the most common being HER2 (breast cancer, three trials), although some utilize a personalized approach with neoantigens (6/20, 30%) (Figure 5c). This evidence concerns the gene ERBB2 and breast carcinoma.